A Clinical Trial Using Methylation Age to Evaluate Current Antiaging Practices

Josh Mitteldorf

DOI: https://doi.org/10.1089/rej.2018.2083

Abstract:Recent advances in the technology of "aging clocks" based on DNA methylation suggest that it may be possible to measure changes in the rate of human aging over periods as short as a year or two. To the extent that methylation (and other biomarkers) are valid surrogates for biological age, the testing of antiaging interventions has thus become radically cheaper, faster, and more practical. Together with colleagues at UCLA, I have initiated a clinical trial to evaluate some of the most popular antiaging strategies currently deployed by "early adopters" in the lay community of personal health activists. We are recruiting 5000 subjects, age 45-65, and interviewing them in detail about their diet, drugs and supplements, exercise, social, and other practices that plausibly contribute to modulate the rate of aging. They agree to submit blood samples for analysis of methylation age at the beginning, middle, and end of a 2-year test period. Primary endpoint is the difference in methylation age over the course of 2 years. We are in the process of developing a specialized clock, optimized for individual differences over time. Results will be viewed as an exploratory study to identify synergistic combinations of age-retarding treatments. It is our expectation that there is a great deal of redundancy in the strategies that have been researched and promoted to the aware public; thus, most combinations can retard the rate of aging by only a few percent, consistent with the best known single measures. However, we hope that among the many strategies that our subjects have adopted, there will be some combinations that synergize and achieve age retardation by ≥25% or more. A mock-up analysis of computer-generated data has been performed to fix parameters of the study, and confirm that such combinations will be able to be detected with good probability, should they exist. All data (redacted for privacy) will be open sourced, available to the scientific community and to the public.